Current issue #17, 2015

Yes probably no

Discussion on potential deregulation of advertising Rx drugs in the media gaining momentum

The Russian media, with an increased and quite explainable interest, have been watching the fate of the Ministry for Communications and the Media proposal on temporary deregulation of media advertising of specific goods, including Rx drugs. The agencies involved in this work have been extremely wary when commenting on this idea’s prospects and are in no hurry to support the media in their hope for a favorable decision. Experts doubt that deregulation of Rx drug advertising may be beneficial for the industry, however, proceeding from this initiative generation background, concede that this proposal will be implemented.

[PharmVestnik # 17, 26/05/2015, p. 1, cont’d p. 4]

Pharma industry seeking for a driver

The keynote of the 21^st Russian Pharmaceutical Forum hosted in St. Petersburg on May 19—21, was the topic of the economic crisis – and not only in Russia. How can the interests of the pharma industry and the state be harmonized in a tough financial situation? Do companies have adaptive market strategies? Is investing in the Russian pharma sector promising today? The forum participants were looking for answers both to the above-listed and some other questions.

[PharmVestnik # 17, 26/05/2015, pp. 2-3]

The history of an acquisition

Interros will be developing its pharmaceutical asset

Research and Production Association Petrovax Pharm, one of the few Russian enterprises that managed to market its R&D results, started actively looking for a partner three years ago. It turned out to be highly sought-after. It sparked an interest of such giants as Abbott and Pharmstandard. As a result, the company’s controlling share was sold to Vladimir Potanin, the owner of Interros Group. This deal struck the market as unexpected. Rumor had it that Interros intended to resell this asset. An opportunity presented itself for PharmVestnik reviewer Elena Kalinovskaya to ask directly Natalia PUCHKOVA, Petrovax Pharm’s co-owner and Deputy Chairman of the Board.

[PharmVestnik # 17, 26/05/2015, p. 5]

Pressed on all sides

Distribution businesses adjusting to new reality

“The health of the entire pharmaceutical market depends on how distributors are doing”; these were the opening words by Andrey Obruchnikov, Takeda Russia’s Commercial and Logistics Director, who moderated the distribution network session at the 21^s...